Intarcia Therapeutics’ GLP-1 agonist product candidate for type 2 diabetes now belongs to i2o Therapeutics, which will make the treatment’s case for approval at an upcoming FDA advisory committee meeting. The startup’s $46 million Series A financing is one of several recently announced funding rounds.
It's safe to say Ed Mathers has accrued some industry know-how after 35 years in the biopharma industry — 15 of which have been spent on the investor side. So what's his take on today's high potential therapeutic areas?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Top-selling diabetes drug Januvia may get a run for its money: Boston-based Intarcia Therapeutics released Phase 3 results saying its implantable device is more effective in treating diabetes and obesity than Januvia.